title: Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers.
abstract: BACKGROUND
  Dipeptidyl peptidase (DPP)-4 inhibitors, a novel oral anti-diabetic agents, exert a protective effect on pancreatic β-cell function in patients with type 2 diabetic mellitus (T2DM). However, their beneficial effect in hypertensive T2DM patients treated with angiotensin receptor blockers (ARBs) has not been investigated.
  
  
  METHODS
  In this open-label multicenter randomized study, a total of 55 hypertensive T2DM patients treated with ARBs were randomly assigned to receive the DPP-4 inhibitor sitagliptin or sulfonylurea (SU).
  
  
  RESULTS
  After 24 weeks of treatment, a significant reduction in fasting blood glucose was only observed in the sitagliptin group, while HbA1c was significantly reduced in both groups. Homeostasis model assessment of insulin resistance was not significantly improved in either group. Indicators of pancreatic β-cell function, including proinsulin to insulin ratio and homeostasis model assessment of β-cell function, were significantly improved in the sitagliptin group, but not in the SU group. The beneficial effects of sitagliptin were observed in hypoglycemic drug naïve patients, but not in patients who had received SU monotherapy prior to the study.
  
  
  CONCLUSIONS
  Treatment with the DPP-4 inhibitor sitagliptin might exert beneficial effects on pancreatic β-cell function in ARB-treated T2DM patients and its efficacy might be more pronounced in hypoglycemic drug naïve patients.
authors.affiliation: Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Japan.
authors.forename: Kensuke
authors.initials: K
authors.lastname: Fukui
authors.affiliation: Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kawahito
authors.affiliation: Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Japan.
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Wakana
authors.affiliation: Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Japan.
authors.forename: Masakazu
authors.initials: M
authors.lastname: Kikai
authors.affiliation: Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Japan.
authors.forename: Kensuke
authors.initials: K
authors.lastname: Terada
authors.affiliation: Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Japan.
authors.forename: Keita
authors.initials: K
authors.lastname: Yamamoto
authors.affiliation: Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Irie
authors.affiliation: Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Japan.
authors.forename: Taku
authors.initials: T
authors.lastname: Kato
authors.affiliation: Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Japan.
authors.forename: Sonoko
authors.initials: S
authors.lastname: Miyagawa
authors.affiliation: Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Japan hiyamada@koto.kpu-m.ac.jp.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Yamada
mesh_terms: D000368:Aged; D057911:Angiotensin Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000473:pathology*; D008297:Male; D000068900:Sitagliptin Phosphate / Q000494:pharmacology / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use
chemical_list: D057911:Angiotensin Receptor Antagonists; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D000068900:Sitagliptin Phosphate
keywords: Type 2 diabetes mellitus; angiotensin receptor blockers; dipeptidyl peptidase-4 inhibitors; pancreatic β-cell function; proinsulin